XM does not provide services to residents of the United States of America.

Rupee on course for best week in 2024, forward premiums maintain uptrend



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>INDIA RUPEE-Rupee on course for best week in 2024, forward premiums maintain uptrend</title></head><body>

By Jaspreet Kalra

MUMBAI, Sept 20 (Reuters) -The Indian rupee strengthened against the U.S. dollar on Friday and was on course to post its best weekly gain this year, after the Federal Reserve embarked on its policy easing cycle with an oversized 50-basis-point interest rate cut earlier in the week.

The rupee INR=IN rose 0.1% to 83.5450 against the dollar, as of 10:35 a.m. IST, up from Thursday's close at 83.68.

Dollar offers from foreign banks alongside likely unwinding of dollar-rupee long positions in the non-deliverable forwards (NDF) market helped lift the rupee on Friday, a trader at a state-run bank said.

The rupee has logged consecutive gains over the last five trading sessions and is up 0.4% week-on-week, on course for its best weekly gain since December 2023.

Alongside the Fed's rate cut, an improvement in portfolio inflows has helped the local currency. Overseas investors have net bought more than $7 billion of local stocks and bonds over September, their highest monthly inflows over 2024.

The dollar index was hovering close to its year-to-date low of 100.5, while most Asian currencies climbed.

The Reserve Bank of India also seems to have "loosened its iron grip on the USD/INR pair", contributing to the recent price action, said Anil Kumar Bhansali, head of treasury at Finrex Treasury Advisors.

Meanwhile, dollar-rupee forward premiums continued to rise, with the 1-year implied yield INRANPRM1Y=RR up 3 basis points at 2.35%, its highest level since April 2023.

The 1-year implied yield has risen 11 bps over September so far, boosted by expectations that the Fed will push borrowing costs lower.

Odds of another 50-bp rate cut by the Fed in November have risen to 43%, up from 37% a day earlier, according to CME's FedWatch tool.



Reporting by Jaspreet Kalra; Editing by Rashmi Aich

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.